[New] After the announced transition period, the Saskatchewan Drug Plan will no longer cover the reference biologic medication.
Government of Saskatchewan
[New] Patients who are currently using an affected reference biologic medication will need to transition to a biosimilar version by the end of the announced transition period to maintain Saskatchewan Drug Plan coverage of their treatment.
Government of Saskatchewan
[New] Pharmaceutical companies such as Amgen, Eli Lilly, and Pfizer are expected to grow their leadership by investing in new injectables, patient support programs, and education for specialists.
Precedence Research
[New] Starting in 2028, prescription drug plan sponsors must allow any pharmacy meeting standard contract terms and conditions to participate in their networks.
Buchanan Ingersoll & Rooney PC
[New] Pharmaceutical supply chain integrity is critical for patient safety, with counterfeit medications representing a significant global health threat.
Mobile App Development Company
[New] By Drug Type, the hormone replacement therapy (HRT) segment is expected to expand at the fastest CAGR of 8.1% between 2024 and 2034 By Distribution Channel, the retail pharmacy segment captured more than 39% of revenue share in 2023.
Precedence Research
[New] The 2026 regulatory environment in the EU is tightening, with new pharmaceutical legislation aimed at reducing the period of data exclusivity for new drugs, which could impact long-term profitability. / UK
The Chronicle-Journal
[New] Reductions in NIH funding and regulatory delays could result in dozens fewer new drug approvals and disrupt tens of thousands of patients enrolled in clinical trials.
AJMC
[New] Health officials are warning that drug poisonings are on the rise across B.C., with a new single-day record for most drug poisonings attended by paramedics being set last week.
CBC
[New] The Union Budget 2026-27 has announced Biopharma SHAKTI, a Rs10,000 crore initiative aimed at strengthening India's biologics and biosimilars ecosystem, signalling a strategic shift from generic drug manufacturing to high-value, innovation-driven biopharmaceuticals.
KPs 21st Century IAS Academy
The US Food and Drug Administration has approved Ozempic tablets, an oral form of semaglutide, with availability expected in the United States in the second quarter of 2026.
Rejoy Health
Biogen is betting that growth from newer drugs - including Alzheimer's treatment Leqembi and rare-disease drugs Skyclarys and Spinraza - will offset its declining multiple sclerosis medicines as competition from generics erode sales.
The Edge Malaysia
By 2026, digital transformation in the pharmaceutical industry will no longer be about isolated technologies, but integration.
Voka
AI-powered pharmacogenomics could reduce adverse drug reactions by up to 30% and improve therapeutic efficacy by 25% across major drug classes.
BUSINESS 2.0 NEWS
With a projected 32.6% CAGR through 2029 and genome sequencing costs plummeting toward $200, AI-powered genomics is reshaping personalized medicine, drug discovery, and clinical diagnostics across the global healthcare ecosystem.
BUSINESS 2.0 NEWS
Pfizer's oncology drug Ibrance will likely see generic competition in 2027, with cardiovascular offerings Eliquis and Vyndaqel next up in 2028.
Nasdaq
Drug-resistant infections could cause 10 million deaths annually by 2050, surpassing deaths from cancer. / USA
Market.us Media
Last updated: 17 February 2026
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
